Evidence map›Paper›PMID 34723236›Full record

ArticleJournal of mass spectrometry and advances in the clinical lab2021

Development and Validation of a Novel LC-MS/MS Assay for C-Peptide in Human Serum.

Benjamin Y Owusu, Hannah Pflaum, Russell Garner, North Foulon, Thomas J Laha, Andrew N Hoofnagle

Open access · goldAbstract read
In one paragraph

Article in Journal of mass spectrometry and advances in the clinical lab, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. MRM-based LC-MS method for accurate C-peptide quantitation.Journal of mass spectrometry and advances in the clinical lab · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Clinical Proteomics for Solid Organ Tissues.Molecular & cellular proteomics : MCP · 2023
    Article
  8. Article
  9. Multiplexed quantification of insulin and C-peptide by LC-MS/MS without the use of antibodies.Journal of mass spectrometry and advances in the clinical lab · 2022
    Article
  10. Listening to your mass spectrometer: An open-source toolkit to visualize mass spectrometer data.Journal of mass spectrometry and advances in the clinical lab · 2022
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Benjamin Y OwusuDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Hannah PflaumDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Russell GarnerDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
North FoulonDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Thomas J LahaDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
Andrew N HoofnagleDepartment of Laboratory Medicine, University of Washington, Seattle, WA.
University of Washington · US

Funding

Vector and Transgenic Mouse CoreP30DK017047 · NIDDK · UNIVERSITY OF WASHINGTON · PI Karin E Bornfeldt · 1986 to 2026
$41.4M
Quantifying proteins in plasma to democratize personalized medicine for patients with type 1 diabetesU01DK121289 · NIDDK · UNIVERSITY OF WASHINGTON · PI HOOFNAGLE, ANDREW N · 2019 to 2021
$1.9M
NIDDK NIH HHS P30 DK017047NIDDK NIH HHS U01 DK121289
6 · The paper itself

Abstract

introductionC-peptide is used as a marker of endogenous insulin secretion in the assessment of residual β-cell function in diabetes and in the diagnostic workup of hypoglycemia. Previously developed LC-MS/MS methods to quantify serum concentrations of C-peptide have monitored intact peptide, which ionizes poorly. As a result, methods have leveraged immunoaffinity enrichment or two-dimensional chromatography. In this study, we aimed to use proteolysis during sample preparation to enhance the sensitivity of traditional LC-MS/MS.

methodsDue to the absence of arginine and lysine residues in C-peptide, we utilized Glu-C as the proteolytic enzyme in the method. After protein precipitation using acetonitrile and solid phase extraction with mixed anion exchange, lower molecular weight polypeptides were reduced, alkylated, and proteolyzed. The two amino-terminal peptide fragments, EAEDLQVGQVE and LGGGPGAGSLQPLALE, were monitored using multiple reaction monitoring in positive ion mode (Acquity ULPC-Xevo TQ-S, Waters). The former peptide was used for quantification and the latter for quality assurance.

resultsGlu-C was determined to be a reliable proteolytic enzyme with monotonic digestion kinetics. The assay was linear between 0.1 and 15 ng/mL and had a lower limit of quantification of 0.06 ng/mL. Total imprecision was 7.7 %CV and long-term imprecision at 0.16 ng/mL was 10.0%. Spike-recovery experiments demonstrated a mean recovery of 98.2 % (± 9.1 %) and the method compared favorably with a commercially available immunoassay and a reference measurement procedure.

conclusionProtein precipitation with solid phase extraction and proteolysis with Glu-C is a robust sample preparation method for quantification of C-peptide in human serum by LC-MS/MS.

Indexed as

C-peptideLC-MS/MSliquid chromatography-tandem mass spectrometryserumvalidation

Identifiers

PMID34723236
PMCPMC8553002
OpenAlexW3116561883

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.